Papers

10

Total Citations

114

H-Index

6

About

Dr. Jian‐Ri Li is a leading urologic oncologist whose research bridges genetic susceptibility and surgical innovation in prostate and renal cancers. His work focuses on how long non‑coding RNA polymorphisms—particularly in GAS5, MALAT1, and H19—influence prostate cancer risk, progression, and lymph node metastasis. Notably, his 2019 study on GAS5 variant rs145204276 (27 citations) demonstrated that this polymorphism significantly affects prostate cancer susceptibility and clinicopathologic features, providing a potential biomarker for risk stratification. Dr. Li also pioneered the use of robotic surgery in urology, reporting the long‑term outcomes of robotic partial nephrectomy for renal angiomyolipoma (17 citations) and standardizing the robotic‑assisted radical prostatectomy procedure after 1,200 cases. His work on carbonic anhydrase 9 expression (15 citations) offers a novel predictor for nodal metastasis in patients with low PSA levels. With over 100 total citations, Dr. Li’s contributions have advanced both the molecular understanding of urologic cancers and the refinement of minimally invasive surgical techniques, directly impacting patient selection and treatment outcomes.

Research Focus

Key Achievements

6
H-Index
10
Papers
114
Total Citations
11
Avg Citations/Paper
🏆 Most Cited Paper
Impact of GAS5 genetic polymorphism on prostate cancer susceptibility and clinicopathologic characteristics
27 citations · 2019
📈 Most Prolific Year: 2019 (2 Papers)
🤝 Key Collaborators: 46
🏛 Institutions: Chung Shan Medical University, Taichung Veterans General Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago